中国临床药理学杂志2025，Vol.41Issue(16)：2257-2262,6.DOI:10.13699/j.cnki.1001-6821.2025.16.002
阿利沙坦酯联合吲达帕胺治疗轻中度原发性高血压合并冠心病患者的临床研究
Clinical trial of allisartan isoproxil combined with indapamide in patients with endemic mild to moderate primary hypertension complicated by coronary heart disease
摘要
Abstract
Objective To study the efficacy and safety of allisartan isoproxil tablet combined with indapamide tablet in the treatment of patients with mild to moderate essential hypertension and coronary heart disease.Methods Patients with mild to moderate essential hypertension and coronary heart disease were divided into treatment group and control group using the cohort method.The control group was given oral indapamide tablets 2.5 mg once a day based on the conventional treatment regimen.The treatment group was given allisartan isoproxil tablets 240 mg once a day in addition to the control group's regimen for a total of 12 weeks.The clinical efficacy,24-hour blood pressure variability,cardiac function,vascular endothelial function and safety evaluation of the two groups were compared.Results A total of 105 patients were enrolled,including 54 patients in treatment group and 51 patients in control group.After treatment,the total clinical effective rate of the treatment group was 90.74％(49 cases/54 cases),and that of control group was 72.55％(37 cases/51 cases),which was significantly higher in treatment group than in control group(P＜0.05).After treatment,the daytime(d)systolic blood pressure variability(SBPV)levels in treatment group and control group were(11.32±2.13)and(12.48±2.26)mmHg,respectively;the nighttime(n)SBPV levels were(10.03±1.79)and(10.82±2.10)mmHg,respectively;the d diastolic blood pressure variability(DBPV)levels were(8.66±1.51)and(9.36±1.57)mmHg,respectively;the nDBPV levels were(8.05±1.32)and(8.68±1.62)mmHg,respectively;the 24 h SBPV levels were(10.85±2.20)and(11.96±2.05)mmHg,respectively;the 24 h DBPV levels were(9.67±1.93)and(10.66±1.92)mmHg,respectively;the brain natriuretic peptide(BNP)levels were(83.47±10.53)and(89.41±13.19)ng·L-1,respectively;the endothelin-1(ET-1)levels were(55.44±9.27)and(60.36±10.86)ng·L-1,respectively;and the Apelin levels were(36.44±6.41)and(34.22±4.37)ng·mL-1,respectively.The above metrics showed significant differences between the two groups(P＜0.05,P＜0.01).The adverse drug reactions in treatment group included diarrhea,fever,fatigue,palpitations,soreness in both knee joints,cough,insomnia,decreased appetite and orthostatic hypotension.The adverse drug reactions in control group included diarrhea,headache,decreased appetite,insomnia and orthostatic hypotension.The total incidence of adverse drug reactions in treatment group was 22.22％(12 cases/54 cases),and that in control group was 17.65％(9 cases/51 cases).There was no statistically significant difference(P＞0.05).Conclusion The application of allisartan isoproxil combined with indapamide in treatment of patients with mild to moderate essential hypertension and coronary heart disease can achieve significant therapeutic effects,regulate 24-hour blood pressure variability,improve cardiac function,vascular endothelial function,and quality of life,also demonstrate good safety.关键词
阿利沙坦酯片/吲达帕胺片/原发性高血压/冠心病/疗效Key words
allisartan isoproxil tablet/indapamide tablet/essential hypertension/coronary heart disease/efficacy分类
医药卫生引用本文复制引用
汪春庆,陈志洁,张盈利..阿利沙坦酯联合吲达帕胺治疗轻中度原发性高血压合并冠心病患者的临床研究[J].中国临床药理学杂志,2025,41(16):2257-2262,6.基金项目
青海省科技计划基金资助项目(2021-ZJ-768) （2021-ZJ-768）
